Yamashita Health Care Swings to a ¥131 Million First-Quarter Operating Loss as Hospital Equipment Spending Falls and Staff Costs Rise

More procedures, fewer equipment orders

Yamashita Health Care Holdings, Inc. (TSE: 9265), the Fukuoka-based group whose core operating subsidiary distributes medical equipment and consumables to hospitals, published consolidated results for the first quarter of FY5/2027, the period from June 1 to August 31, 2026, on September 30, 2026 under Japanese GAAP. Revenue slipped 0.2% to ¥15,045 million; the company posted an operating loss of ¥131 million against a ¥36 million profit a year earlier, an ordinary loss of ¥106 million against a ¥67 million profit, and a net loss attributable to owners of the parent of ¥101 million, or ¥39.98 per share, against a ¥2 million loss.

The company says demand for consumables such as treatment materials grew as the number of examinations and operations rose, but hospitals' spending on equipment fell from a year earlier. It describes hospitals squeezed by continuing rises in personnel, utility and medical-material costs, with profitability not improving enough, and therefore cautious about capital investment and procurement.

A thinner gross margin and higher overheads

Cost of sales edged up 0.2% to ¥13,147 million while revenue edged down, so gross profit fell 3.3% to ¥1,897 million and the gross margin narrowed from 13.0% to 12.6%. Selling, general and administrative expenses rose 5.4% to ¥2,029 million, which the company attributes chiefly to higher personnel costs. The ¥65 million drop in gross profit and the ¥104 million increase in overheads together account for the ¥167 million swing from operating profit to loss. A ¥6 million gain on the sale of investment securities and income taxes of just ¥1 million, against ¥71 million a year earlier, left the net loss close to the pre-tax loss of ¥100 million.

Equipment sales fall 21%, consumables grow

The Medical Device Sales segment, almost all of the group, produced revenue of ¥15,068 million (−0.1%) including internal sales, and segment profit fell 40.5% to ¥212 million. By product field, general equipment — general fixtures plus imaging systems such as MRI and CT, radiological equipment and ultrasound — fell 21.2% to ¥1,250 million, and information and services, mainly facility maintenance, fell 21.4% to ¥279 million. General consumables, the largest field, grew 4.9% to ¥6,815 million; minimally invasive treatment, covering endoscopy, surgical and cardiovascular products, rose 1.9% to ¥3,540 million; and specialty fields, led by dialysis and orthopaedic products, were flat at ¥3,182 million.

The Device Manufacturing & Sales segment, which makes the group's own orthopaedic implants and develops ultrasound-based devices, held revenue at ¥54 million and narrowed its segment loss to ¥20 million from ¥63 million. The Medical Mall segment earned ¥1 million on ¥17 million of mainly rental revenue. Corporate costs not allocated to segments rose to ¥311 million from ¥248 million.

Cash spent on a logistics centre and on paying suppliers

Total assets fell ¥1,691 million to ¥25,397 million from May 31, 2026. Cash and deposits dropped to ¥1,918 million from ¥4,127 million, while construction in progress rose to ¥1,421 million from ¥862 million as the core subsidiary expands its Tosu logistics centre and installs material-handling equipment — automated warehousing, transport robots and warehouse-management systems — to automate operations. On the other side, electronically recorded obligations to suppliers fell by ¥1,878 million as payables carried at the year end fell due, and the company took on ¥1,000 million of short-term borrowings as working capital to settle them. Net assets fell to ¥9,034 million; with the smaller balance sheet, the equity ratio rose from 34.6% to 35.6%.

Guidance and dividend unchanged

The company left unchanged the full-year forecast it published on July 13, 2026: revenue of ¥69,794 million (+8.8%), operating profit of ¥833 million (+13.1%), ordinary profit of ¥855 million (−2.4%) and profit attributable to owners of the parent of ¥553 million (−14.6%), or ¥217.65 per share. FY5/2027 is the final year of its medium-term management plan. The dividend forecast is also unchanged at a year-end ¥65.00 per share, against ¥107.00 for FY5/2026; the filing gives no reason for the lower payout.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.